Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
|
|
Pasithea Therapeutics Corp.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 01/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 12/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Fi...|
Docs:
|
"SETTLEMENT AND COOPERATION AGREEMENT This Settlement and Cooperation Agreement is made and entered into as of December 9, 2022, by and among Pasithea Therapeutics Corp. , on the one hand, and Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP, David Delaney, Avi Geller, and Eric Shahinian , on the other hand . RECITALS",
"Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group MIAMI BEACH, Fla., Dec. 12, 2022 -- Pasithea Therapeutics Corp. , a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system disorders, today announced that it has reached a comprehensive Settlement and Cooperation Agreement with Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP, David Delaney, Avi Geller, and Eric Shahinian resolving all outstanding issues between the parties. Pursuant to the Agreement, the Camac Group has agreed to a three-year standstill provision and the parties have agreed to dismiss with prejudice the pending Delaware litigatio..." |
|
| 10/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ... |
| 09/20/2022 |
8-K
| Resignation/termination of a director |
| 08/29/2022 |
8-K/A
| Financial Statements and Exhibits Interactive Data |
| 06/27/2022 |
8-K/A
| Quarterly results |
| 06/24/2022 |
8-K/A
| Quarterly results |
| 06/23/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/22/2022 |
8-K
| Quarterly results |
| 06/09/2022 |
8-K
| Quarterly results |
| 12/21/2021 |
8-K
| Quarterly results |
| 11/29/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"PLACEMENT AGENT AGREEMENT DATED NOVEMBER 24, 2021",
"FORM OF SECURITIES PURCHASE AGREEMENT",
"FORM OF WARRANTS",
"FORM OF REGISTRATION RIGHTS AGREEMENT",
"Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced At a Premium to the Market Under Nasdaq Rules Miami Beach, FL, November 24, 2021 -- Pasithea Therapeutics Corp. , a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 million shares of its common stock and warrants to purchase 8.68 million shares of its common stock, at a purchase price of $3.50 per share and accompanying warrant in a private placement priced at a premium to the market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected to be approximat..." |
|
|
|